The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Table of contents


Chemical Compound Review

rutoside     sodium2-hydroxy-4-[5-hydroxy- 4-oxo-7...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of 2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-7-sulfooxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5S,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxy-chromene


Psychiatry related information on 2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-7-sulfooxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5S,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxy-chromene


High impact information on 2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-7-sulfooxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5S,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxy-chromene

  • These experimental studies may help to explain former clinical investigations showing that Phlogenzym (PHL), a preparation consisting of the proteases bromelain and trypsin and the antioxidant rutosid, ameliorate certain diseases with an underlying inflammatory process [6].
  • METHODS: In an open pilot study, oral rutoside (50 mg twice a day) and ascorbic acid (500 mg twice a day) were administered to 3 patients with chronic PPP [7].
  • It is concluded that rutoside has an acute anti-inflammatory activity in this model which may be related to a putative direct protective effect on intestinal cells, mainly enterocytes, in which the antioxidative properties of the flavonoid may play a role [8].
  • MAIN RESULTS: Three trials, involving 159 women, were included.Varicose veinsOne trial, involving 69 women, reported that rutoside significantly reduced the symptoms associated with varicose veins (relative risk (RR) 1.89, 95% confidence interval (CI) 1.11 to 3.22) [9].
  • The treatment of progressive pigmented purpura with ascorbic acid and a bioflavonoid rutoside [10].

Chemical compound and disease context of 2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-7-sulfooxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5S,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxy-chromene


Biological context of 2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-7-sulfooxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5S,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxy-chromene


Anatomical context of 2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-7-sulfooxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5S,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxy-chromene


Associations of 2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-7-sulfooxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5S,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxy-chromene with other chemical compounds


Gene context of 2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-7-sulfooxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5S,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxy-chromene

  • In vitro, 0-/-B-hydroxyethyl/rutoside significantly inhibited platelet adhesion to bovine ECM in concentrations of 20 micrograms/ml PRP, and with 30 micrograms/ml the PRP adhesion to glass and spreading were inhibited [15].

Analytical, diagnostic and therapeutic context of 2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-7-sulfooxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5S,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxy-chromene

  • One group (n = 8) was treated with daily intraperitoneal injections of 12 mg of a protease formulation containing trypsin, bromelain and rutosid, and another group (n = 8) with placebo [18].
  • Age-adjusted analysis of tumor rates did not provide any evidence for rutin sulfate to be carcinogenic under the conditions of this bioassay [19].
  • Fourteen male Wistar rats underwent 5/6 nephrectomy, and were randomized into a control group (C, n = 7) given 2 ml of 0.9% NaCl intraperitoneally (i.p.) daily, and a study group (P, n = 7) treated with 12 mg Phlogenzym (combination of trypsin, bromelain, and rutosid) in 2 ml saline i.p. daily [20].


  1. A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis. Baumhackl, U., Kappos, L., Radue, E.W., Freitag, P., Guseo, A., Daumer, M., Mertin, J. Mult. Scler. (2005) [Pubmed]
  2. Prevention of murine EAE by oral hydrolytic enzyme treatment. Targoni, O.S., Tary-Lehmann, M., Lehmann, P.V. J. Autoimmun. (1999) [Pubmed]
  3. Oral administration of rutoside can ameliorate inflammatory bowel disease in rats. Cruz, T., Gálvez, J., Ocete, M.A., Crespo, M.E., Sánchez de Medina L-H, F., Zarzuelo, A. Life Sci. (1998) [Pubmed]
  4. Protease administration decreases enhanced transforming growth factor-beta 1 content in isolated glomeruli of diabetic rats. Paczek, L., Gaciong, Z., Bartlomiejczyk, I., Sebekova, K., Birkenmeier, G., Heidland, A. Drugs under experimental and clinical research. (2001) [Pubmed]
  5. Anticatatonic effect of venoruton. Aley, K.O., Kulkarni, S.K. Methods and findings in experimental and clinical pharmacology. (1988) [Pubmed]
  6. Administration of proteolytic enzymes bromelain and trypsin diminish the number of CD4+ cells and the interferon-gamma response in Peyer's patches and spleen in endotoxemic balb/c mice. Manhart, N., Akomeah, R., Bergmeister, H., Spittler, A., Ploner, M., Roth, E. Cell. Immunol. (2002) [Pubmed]
  7. Treatment of progressive pigmented purpura with oral bioflavonoids and ascorbic acid: an open pilot study in 3 patients. Reinhold, U., Seiter, S., Ugurel, S., Tilgen, W. J. Am. Acad. Dermatol. (1999) [Pubmed]
  8. Rutoside as mucosal protective in acetic acid-induced rat colitis. Gálvez, J., Cruz, T., Crespo, E., Ocete, M.A., Lorente, M.D., Sánchez de Medina, F., Zarzuelo, A. Planta Med. (1997) [Pubmed]
  9. Interventions for varicose veins and leg oedema in pregnancy. Bamigboye, A., Smyth, R. Cochrane database of systematic reviews (Online) (2007) [Pubmed]
  10. The treatment of progressive pigmented purpura with ascorbic acid and a bioflavonoid rutoside. Laufer, F. Journal of drugs in dermatology : JDD. (2006) [Pubmed]
  11. Oral enzyme combination versus diclofenac in the treatment of osteoarthritis of the knee--a double-blind prospective randomized study. Akhtar, N.M., Naseer, R., Farooqi, A.Z., Aziz, W., Nazir, M. Clin. Rheumatol. (2004) [Pubmed]
  12. Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy. Rahn, R., Adamietz, I.A., Boettcher, H.D., Schaefer, V., Reimer, K., Fleischer, W. Dermatology (Basel) (1997) [Pubmed]
  13. Effect of a combination of coumarin derivatives and rutoside on venous and lymphatic circulations during severe constriction of the caudal vena cava in rabbits. Borzeix, M.G., Angignard, J., Dedieu, F., Dupont, J.M., Miloradovich, T., Leutenegger, E. Arzneimittel-Forschung. (1995) [Pubmed]
  14. Rutoside and the X-ray induced damage in jejunal mucosa of mouse. Rao, K.R., Fritz-Niggli, H. Strahlentherapie. (1984) [Pubmed]
  15. Effects of 0-/-B-hydroxyethyl/rutoside on platelet function and thrombus formation in rat mesenteric vessels. Krupiński, K., Breddin, H.K., Giedrojć, J., Bodzenta-Lukaszyk, A., Bielawiec, M. Materia medica Polona. Polish journal of medicine and pharmacy. (1995) [Pubmed]
  16. Mast-cell heterogeneity in the rat. Damas, J., Lecomte, J. Experientia (1983) [Pubmed]
  17. An open-label, randomized multicenter study comparing the efficacy and safety of Cyclo 3 Fort versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency. Beltramino, R., Penenory, A., Buceta, A.M. Angiology. (2000) [Pubmed]
  18. Beneficial effect of proteases on allograft arteriosclerosis in a rat aortic model. Gaciong, Z., Paczek, L., Bojakowski, K., Socha, K., Wisniewski, M., Heidland, A. Nephrol. Dial. Transplant. (1996) [Pubmed]
  19. Negative dose-response study for carcinogenicity of orally administered rutin sulfate in Sprague-Dawley rats. Habs, M., Habs, H., Berger, M.R., Schmähl, D. Cancer Lett. (1984) [Pubmed]
  20. Effects of protease therapy in the remnant kidney model of progressive renal failure. Sebekova, K., Paczek, L., Dämmrich, J., Ling, H., Spustova, V., Gaciong, Z., Heidland, A. Mineral and electrolyte metabolism. (1997) [Pubmed]
WikiGenes - Universities